{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T18:20:21Z","timestamp":1794939621485,"version":"4.9.1"},"reference-count":136,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31571493"],"award-info":[{"award-number":["31571493"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31871395"],"award-info":[{"award-number":["31871395"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32170841"],"award-info":[{"award-number":["32170841"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81741043"],"award-info":[{"award-number":["81741043"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine &amp; Growth Factor Reviews"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.cytogfr.2023.03.003","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T12:51:54Z","timestamp":1678884714000},"page":"41-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["Multiple post-translational modifications ensure EGFR functionality: Potential therapeutic targets to overcome its drug-resistance mutations"],"prefix":"10.1016","volume":"70","author":[{"given":"Qiangqiang","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiyu","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hangyang","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yana","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingyu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Qasim","family":"Barkat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Hui","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3316-893X","authenticated-orcid":false,"given":"Ximei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cytogfr.2023.03.003_bib1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib2","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41586-020-1961-1","article-title":"Tobacco smoking and somatic mutations in human bronchial epithelium","volume":"578","author":"Yoshida","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib3","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.0270","article-title":"Association of dietary fiber and yogurt consumption with lung cancer risk: a pooled analysis","volume":"6","author":"Yang","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib4","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s13046-022-02453-8","article-title":"Suppression of VEGFD expression by S-nitrosylation promotes the development of lung adenocarcinoma","volume":"41","author":"He","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib5","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/hep.29350","article-title":"Role of ErbB\/HER family of receptor tyrosine kinases in cholangiocyte biology","volume":"67","author":"Pellat","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib6","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ctrv.2016.12.001","article-title":"Cancer resistance to therapies against the EGFR-RAS-RAF pathway: the role of MEK","volume":"53","author":"Martinelli","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib7","doi-asserted-by":"crossref","first-page":"E3855","DOI":"10.1073\/pnas.1510733112","article-title":"EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function","volume":"112","author":"Phuchareon","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib8","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.apsb.2015.07.001","article-title":"Mechanisms of resistance to EGFR tyrosine kinase inhibitors","volume":"5","author":"Huang","year":"2015","journal-title":"Acta Pharm. Sin. B."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib9","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.drudis.2017.10.004","article-title":"Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors","volume":"23","author":"Singh","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib10","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.apsb.2019.06.010","article-title":"Discovery of WS-157 as a highly potent, selective and orally active EGFR inhibitor","volume":"9","author":"He","year":"2019","journal-title":"Acta Pharm. Sin. B."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib11","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nm.3854","article-title":"Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M","volume":"21","author":"Thress","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib12","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13045-016-0290-1","article-title":"EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer","volume":"9","author":"Wang","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib13","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jtho.2018.05.024","article-title":"EGFR L792H and G796R: two novel mutations mediating resistance to the third-generation EGFR tyrosine kinase inhibitor osimertinib","volume":"13","author":"Zhang","year":"2018","journal-title":"J. Thorac. Oncol.: Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib14","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.jtho.2018.04.005","article-title":"Identification of mutation accumulation as resistance mechanism emerging in first-line osimertinib treatment","volume":"13","author":"Uchibori","year":"2018","journal-title":"J. Thorac. Oncol.: Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib15","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.cell.2006.05.013","article-title":"An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor","volume":"125","author":"Zhang","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib16","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1091\/mbc.E19-09-0548","article-title":"Multisite EGFR phosphorylation is regulated by adaptor protein abundances and dimer lifetimes","volume":"31","author":"Salazar-Cavazos","year":"2020","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib17","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","article-title":"The ErbB\/HER family of protein-tyrosine kinases and cancer","volume":"79","author":"Roskoski","year":"2014","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib18","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccr.2004.10.018","article-title":"HER2\/HER3 heterodimers in prostate cancer: Whither HER1\/EGFR?","volume":"6","author":"Freeman","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib19","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/bs.acr.2020.04.001","article-title":"HER family in cancer progression: from discovery to 2020 and beyond","volume":"147","author":"Kumar","year":"2020","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib20","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1146\/annurev-biochem-060614-034402","article-title":"A structural perspective on the regulation of the epidermal growth factor receptor","volume":"84","author":"Kovacs","year":"2015","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib21","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.cell.2012.12.030","article-title":"Architecture and membrane interactions of the EGF receptor","volume":"152","author":"Arkhipov","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib22","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0092-8674(89)90867-2","article-title":"Functional independence of the epidermal growth factor receptor from a domain required for ligand-induced internalization and calcium regulation","volume":"59","author":"Chen","year":"1989","journal-title":"Cell"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib23","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1016\/S0021-9258(18)53862-X","article-title":"Amphiregulin induces tyrosine phosphorylation of the epidermal growth factor receptor and p185erbB2. Evidence that amphiregulin acts exclusively through the epidermal growth factor receptor at the surface of human epithelial cells","volume":"268","author":"Johnson","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib24","doi-asserted-by":"crossref","first-page":"9966","DOI":"10.1016\/S0021-9258(17)36977-6","article-title":"Recombinant human betacellulin. Molecular structure, biological activities, and receptor interaction","volume":"269","author":"Watanabe","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib25","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1038\/sj.onc.1201458","article-title":"Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4","volume":"15","author":"Komurasaki","year":"1997","journal-title":"Oncogene"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib26","doi-asserted-by":"crossref","first-page":"8503","DOI":"10.1074\/jbc.M413919200","article-title":"Epigen, the last ligand of ErbB receptors, reveals intricate relationships between affinity and mitogenicity","volume":"280","author":"Kochupurakkal","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib27","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S0092-8674(02)00940-6","article-title":"Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha","volume":"110","author":"Garrett","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib28","doi-asserted-by":"crossref","first-page":"5432","DOI":"10.1128\/MCB.00742-10","article-title":"Structural evidence for loose linkage between ligand binding and kinase activation in the epidermal growth factor receptor","volume":"30","author":"Lu","year":"2010","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib29","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.cell.2009.04.025","article-title":"Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment","volume":"137","author":"Jura","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib30","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.cell.2009.06.008","article-title":"The juxtamembrane region of EGFR takes center stage","volume":"137","author":"Hubbard","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13236005","article-title":"The MEK\/ERK\/miR-21 signaling is critical in osimertinib resistance in EGFR-mutant non-small cell lung cancer cells","volume":"13","author":"Huang","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/cancers9050052","article-title":"Epidermal growth factor receptor cell proliferation signaling pathways","volume":"9","author":"Wee","year":"2017","journal-title":"Cancers"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib33","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.3892\/or.2016.4905","article-title":"Correlation of EGFR Del 19 with Fn14\/JAK\/STAT signaling molecules in non-small cell lung cancer","volume":"36","author":"Sun","year":"2016","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib34","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/9016296","article-title":"The interaction of the IFNgamma\/JAK\/STAT1 and JAK\/STAT3 signalling pathways in EGFR-mutated lung adenocarcinoma cells","volume":"2022","author":"Han","year":"2022","journal-title":"J. Oncol."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib35","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/j.bpj.2020.10.008","article-title":"Autophosphorylation of EGFR at Y954 facilitated homodimerization and enhanced downstream signals","volume":"119","author":"Thirukkumaran","year":"2020","journal-title":"Biophys. J."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib36","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.3892\/or.2014.3102","article-title":"Transphosphorylation of EGFR at Y845 plays an important role in its autophosphorylation and kinase activity","volume":"31","author":"Song","year":"2014","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib37","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1038\/onc.2012.418","article-title":"HER2 stabilizes EGFR and itself by altering autophosphorylation patterns in a manner that overcomes regulatory mechanisms and promotes proliferative and transformation signaling","volume":"32","author":"Hartman","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib38","first-page":"5268","article-title":"The epidermal growth factor receptor pathway: a model for targeted therapy","volume":"12","author":"Scaltriti","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222312828","article-title":"The role of EREG\/EGFR pathway in tumor progression","volume":"22","author":"Cheng","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib40","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.yexcr.2008.08.009","article-title":"ErbB receptors in the biology and pathology of the aerodigestive tract","volume":"315","author":"Morgan","year":"2009","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib41","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/1878-0261.12055","article-title":"MAP4K4 is a novel MAPK\/ERK pathway regulator required for lung adenocarcinoma maintenance","volume":"11","author":"Gao","year":"2017","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib42","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1158\/1078-0432.CCR-21-3359","article-title":"HER3 augmentation via blockade of EGFR\/AKT signaling enhances anticancer activity of HER3-targeting patritumab deruxtecan in EGFR-mutated non-small cell lung cancer","volume":"28","author":"Yonesaka","year":"2022","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114864","article-title":"Dictamnine, a novel c-Met inhibitor, suppresses the proliferation of lung cancer cells by downregulating the PI3K\/AKT\/mTOR and MAPK signaling pathways","volume":"195","author":"Yu","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib44","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.lungcan.2022.03.001","article-title":"Osimertinib-induced syndrome of inappropriate secretion of antidiuretic hormone in oncogene-addicted lung adenocarcinoma: a case report","volume":"166","author":"Skribek","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib45","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","article-title":"A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)","volume":"9","author":"Shi","year":"2014","journal-title":"J. Thorac. Oncol.: Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib46","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1016\/S2589-7500(22)00024-3","article-title":"Mining whole-lung information by artificial intelligence for predicting EGFR genotype and targeted therapy response in lung cancer: a multicohort study","volume":"4","author":"Wang","year":"2022","journal-title":"Lancet Digit. Health"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib47","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1146\/annurev-pathol-011110-130206","article-title":"EGFR mutations and lung cancer","volume":"6","author":"da Cunha Santos","year":"2011","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib48","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jtho.2016.12.014","article-title":"Driven by mutations: the predictive value of mutation subtype in EGFR-mutated non-small cell lung cancer","volume":"12","author":"Castellanos","year":"2017","journal-title":"J. Thorac. Oncol.: Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib49","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/S1470-2045(11)70129-2","article-title":"EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications","volume":"13","author":"Yasuda","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib50","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.semcancer.2019.09.015","article-title":"Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer","volume":"61","author":"Harrison","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib51","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/JTO.0b013e3182781e35","article-title":"Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors","volume":"8","author":"Kobayashi","year":"2013","journal-title":"J. Thorac. Oncol.: Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib52","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s40291-017-0290-z","article-title":"Significant improvement in detecting BRAF, KRAS, and EGFR mutations using next-generation sequencing as compared with FDA-cleared kits","volume":"21","author":"Ma","year":"2017","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib53","first-page":"3639","article-title":"Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition","volume":"23","author":"Yano","year":"2003","journal-title":"Anticancer Res."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib54","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1749-6632.2003.tb03208.x","article-title":"Characterization and expression of novel 60-kDa and 110-kDa EGFR isoforms in human placenta","volume":"995","author":"Reiter","year":"2003","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib55","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib56","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.1038\/s41467-021-26770-2","article-title":"Deciphering cell lineage specification of human lung adenocarcinoma with single-cell RNA sequencing","volume":"12","author":"Wang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.635007","article-title":"Immunotherapy in treating EGFR-mutant lung cancer: current challenges and new strategies","volume":"11","author":"To","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib58","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1158\/1078-0432.CCR-15-2266","article-title":"FDA approval of gefitinib for the treatment of patients with metastatic EGFR mutation-positive non-small cell lung cancer","volume":"22","author":"Kazandjian","year":"2016","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib59","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.jtho.2019.12.126","article-title":"Afatinib for the treatment of NSCLC harboring uncommon EGFR mutations: a database of 693 cases","volume":"15","author":"Yang","year":"2020","journal-title":"J. Thorac. Oncol.: Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib60","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib61","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s40265-018-1028-x","article-title":"Dacomitinib: first global approval","volume":"78","author":"Shirley","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/JTO.0b013e3181913c9f","article-title":"EGFR T790M mutation: a double role in lung cancer cell survival?","volume":"4","author":"Suda","year":"2009","journal-title":"J. Thorac. Oncol.: Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib63","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1073\/pnas.0709662105","article-title":"The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP","volume":"105","author":"Yun","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib64","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib65","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.jtho.2020.09.001","article-title":"Safety, efficacy, and pharmacokinetics of almonertinib (HS-10296) in pretreated patients with EGFR-mutated advanced NSCLC: a multicenter, open-label, phase 1 trial","volume":"15","author":"Yang","year":"2020","journal-title":"J. Thorac. Oncol.: Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102105","article-title":"EGFR exon 20 insertions in advanced non-small cell lung cancer: a new history begins","volume":"90","author":"Remon","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib67","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1158\/2159-8290.CD-21-0226","article-title":"Targeting EGFR Exon 20 insertions in non-small cell lung cancer: recent advances and clinical updates","volume":"11","author":"Meador","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib68","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1002\/1878-0261.12710","article-title":"Variability of EGFR exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors","volume":"14","author":"Qin","year":"2020","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib69","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.jtho.2018.06.019","article-title":"Diverse EGFR Exon 20 insertions and co-occurring molecular alterations identified by comprehensive genomic profiling of NSCLC","volume":"13","author":"Riess","year":"2018","journal-title":"J. Thorac. Oncol.: Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib70","doi-asserted-by":"crossref","first-page":"14768","DOI":"10.1038\/ncomms14768","article-title":"Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer","volume":"8","author":"Uchibori","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib71","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib72","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1200\/JCO.20.00505","article-title":"Brigatinib versus crizotinib in advanced ALK inhibitor-naive ALK-positive non-small cell lung cancer: second interim analysis of the phase III ALTA-1L trial","volume":"38","author":"Camidge","year":"2020","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib73","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.jtho.2020.04.014","article-title":"Effective treatment of lung adenocarcinoma harboring EGFR-activating mutation, T790M, and cis-C797S triple mutations by brigatinib and cetuximab combination therapy","volume":"15","author":"Wang","year":"2020","journal-title":"J. Thorac. Oncol.: Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib74","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nature17960","article-title":"Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors","volume":"534","author":"Jia","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib75","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.canlet.2016.11.008","article-title":"EAI045: the fourth-generation EGFR inhibitor overcoming T790M and C797S resistance","volume":"385","author":"Wang","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib76","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1158\/2159-8290.CD-18-0903","article-title":"Single and dual targeting of mutant EGFR with an allosteric inhibitor","volume":"9","author":"To","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib77","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s43018-022-00351-8","article-title":"An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer","volume":"3","author":"To","year":"2022","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib78","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1158\/2159-8290.CD-20-1683","article-title":"Mobocertinib (TAK-788): a targeted inhibitor of EGFR Exon 20 insertion mutants in non-small cell lung cancer","volume":"11","author":"Gonzalvez","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib79","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1158\/2159-8290.CD-20-1598","article-title":"Activity and safety of mobocertinib (TAK-788) in previously treated non-small cell lung cancer with EGFR Exon 20 insertion mutations from a phase I\/II trial","volume":"11","author":"Riely","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib80","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1158\/1535-7163.MCT-17-1206","article-title":"TAS6417, a novel EGFR inhibitor targeting exon 20 insertion mutations","volume":"17","author":"Hasako","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib81","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1158\/1541-7786.MCR-19-0419","article-title":"TAS6417\/CLN-081 is a pan-mutation-selective EGFR tyrosine kinase inhibitor with a broad spectrum of preclinical activity against clinically relevant EGFR mutations","volume":"17","author":"Udagawa","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib82","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1200\/JCO.21.01323","article-title":"Poziotinib in non-small-cell lung cancer harboring HER2 Exon 20 insertion mutations after prior therapies: ZENITH20-2 trial","volume":"40","author":"Le","year":"2022","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib83","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1200\/JCO.21.01113","article-title":"Poziotinib for patients with HER2 Exon 20 mutant non-small-cell lung cancer: results from a phase II trial","volume":"40","author":"Elamin","year":"2022","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2021.100129","article-title":"Decoding post-translational modification crosstalk with proteomics","volume":"20","author":"Leutert","year":"2021","journal-title":"Mol. Cell. Proteom.: MCP"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib85","first-page":"265","article-title":"Post-translational modification of proteins","volume":"67","author":"Krishna","year":"1993","journal-title":"Adv. Enzymol. Relat. Areas Mol. Biol."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib86","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1021\/acs.jproteome.6b00034","article-title":"Global post-translational modification discovery","volume":"16","author":"Li","year":"2017","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib87","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.tplants.2018.09.004","article-title":"Protein language: post-translational modifications talking to each other","volume":"23","author":"Vu","year":"2018","journal-title":"Trends Plant Sci."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib88","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1074\/jbc.M210194200","article-title":"Regulation of receptor tyrosine kinase signaling by protein tyrosine phosphatase-1B","volume":"278","author":"Haj","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib89","first-page":"22","article-title":"Protein kinase C as a therapeutic target in non-small cell lung cancer","author":"Sadeghi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib90","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1158\/2159-8290.CD-12-0103","article-title":"Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors","volume":"2","author":"Ercan","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib91","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.89647","article-title":"Inactivation of ABL kinases suppresses non-small cell lung cancer metastasis","volume":"1","author":"Gu","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib92","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12943-022-01547-3","article-title":"Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR\/Src\/Erk\/SP1 signaling-mediated ERRalpha re-expression","volume":"21","author":"Pan","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib93","doi-asserted-by":"crossref","first-page":"16168","DOI":"10.1074\/jbc.274.23.16168","article-title":"Ca2+\/calmodulin-dependent kinase II phosphorylates the epidermal growth factor receptor on multiple sites in the cytoplasmic tail and serine 744 within the kinase domain to regulate signal generation","volume":"274","author":"Feinmesser","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib94","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/ncb2158","article-title":"Crosstalk between Arg 1175 methylation and Tyr 1173 phosphorylation negatively modulates EGFR-mediated ERK activation","volume":"13","author":"Hsu","year":"2011","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib95","doi-asserted-by":"crossref","first-page":"4529","DOI":"10.1172\/JCI82826","article-title":"PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response","volume":"125","author":"Liao","year":"2015","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib96","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.1172\/JCI85001","article-title":"Old dog, new tricks: extracellular domain arginine methylation regulates EGFR function","volume":"125","author":"Epstein","year":"2015","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib97","doi-asserted-by":"crossref","first-page":"11915","DOI":"10.4238\/2015.October.5.5","article-title":"Relationship of EGFR DNA methylation with the severity of non-small cell lung cancer","volume":"14","author":"Li","year":"2015","journal-title":"Genet. Mol. Res."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib98","doi-asserted-by":"crossref","first-page":"9813","DOI":"10.4238\/2015.August.19.14","article-title":"Study of the methylation patterns of the EGFR gene promoter in non-small cell lung cancer","volume":"14","author":"Pan","year":"2015","journal-title":"Genet. Mol. Res."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib99","first-page":"193","article-title":"Relationship between EGFR promoter region methylation and secondary resistance which may be induced by gefitinib","volume":"18","author":"Wang","year":"2015","journal-title":"Zhongguo fei ai za zhi = Chin. J. lung Cancer"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib100","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/boc.202100052","article-title":"How palmitoylation affects trafficking and signaling of membrane receptors","volume":"114","author":"Jansen","year":"2022","journal-title":"Biol. Cell"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.120257","article-title":"The emerging roles of nitric oxide in ferroptosis and pyroptosis of tumor cells","volume":"290","author":"He","year":"2022","journal-title":"Life Sci."},{"issue":"Pt 2","key":"10.1016\/j.cytogfr.2023.03.003_bib102","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1042\/bj3260369","article-title":"Nitric oxide reversibly inhibits the epidermal growth factor receptor tyrosine kinase","volume":"326","author":"Estrada","year":"1997","journal-title":"Biochem. J."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib103","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.freeradbiomed.2008.10.048","article-title":"S-Nitrosylation of the epidermal growth factor receptor: a regulatory mechanism of receptor tyrosine kinase activity","volume":"46","author":"Murillo-Carretero","year":"2009","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib104","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1101\/gad.1185804","article-title":"Palmitoylation is required for the production of a soluble multimeric Hedgehog protein complex and long-range signaling in vertebrates","volume":"18","author":"Chen","year":"2004","journal-title":"Genes Dev."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib105","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1126\/science.1064437","article-title":"Skinny hedgehog, an acyltransferase required for palmitoylation and activity of the hedgehog signal","volume":"293","author":"Chamoun","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib106","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.devcel.2005.11.017","article-title":"Palmitoylation of the EGFR ligand Spitz by Rasp increases Spitz activity by restricting its diffusion","volume":"10","author":"Miura","year":"2006","journal-title":"Dev. Cell"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib107","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1021\/bi802249x","article-title":"Palmitoylation of the EGF receptor impairs signal transduction and abolishes high-affinity ligand binding","volume":"48","author":"Macdonald-Obermann","year":"2009","journal-title":"Biochemistry"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib108","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.4161\/cc.29338","article-title":"Involvement of de novo synthesized palmitate and mitochondrial EGFR in EGF induced mitochondrial fusion of cancer cells","volume":"13","author":"Bollu","year":"2014","journal-title":"Cell Cycle"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib109","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.molcel.2016.04.003","article-title":"Inhibition of DHHC20-mediated EGFR palmitoylation creates a dependence on EGFR signaling","volume":"62","author":"Runkle","year":"2016","journal-title":"Mol. Cell"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib110","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.cell.2012.08.029","article-title":"Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing","volume":"150","author":"Imielinski","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib111","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.bbrc.2017.09.044","article-title":"Induced sensitivity to EGFR inhibitors is mediated by palmitoylated cysteine 1025 of EGFR and requires oncogenic Kras","volume":"493","author":"Kharbanda","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib112","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aax2364","article-title":"Blocking EGFR palmitoylation suppresses PI3K signaling and mutant KRAS lung tumorigenesis","volume":"13","author":"Kharbanda","year":"2020","journal-title":"Sci. Signal."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib113","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201708313","article-title":"Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non-small cell lung cancer","volume":"10","author":"Ali","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib114","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/ncb983","article-title":"Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation","volume":"5","author":"Haglund","year":"2003","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib115","doi-asserted-by":"crossref","first-page":"21323","DOI":"10.1074\/jbc.C300096200","article-title":"Endocytosis of receptor tyrosine kinases is driven by monoubiquitylation, not polyubiquitylation","volume":"278","author":"Mosesson","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib116","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.1073\/pnas.1503262112","article-title":"N-Glycosylation as determinant of epidermal growth factor receptor conformation in membranes","volume":"112","author":"Kaszuba","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib117","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/prot.25314","article-title":"Role of N-glycosylation in EGFR ectodomain ligand binding","volume":"85","author":"Azimzadeh Irani","year":"2017","journal-title":"Proteins"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib118","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1091\/mbc.e06-02-0142","article-title":"Activated Cdc42-associated kinase 1 is a component of EGF receptor signaling complex and regulates EGF receptor degradation","volume":"18","author":"Shen","year":"2007","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib119","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.bbrc.2010.07.096","article-title":"COPI-mediated retrograde trafficking from the Golgi to the ER regulates EGFR nuclear transport","volume":"399","author":"Wang","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib120","doi-asserted-by":"crossref","first-page":"9229","DOI":"10.1158\/0008-5472.CAN-07-1333","article-title":"The phosphoinositide kinase PIKfyve mediates epidermal growth factor receptor trafficking to the nucleus","volume":"67","author":"Kim","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib121","doi-asserted-by":"crossref","first-page":"5157","DOI":"10.1021\/acs.biochem.5b00640","article-title":"The nucleus-localized epidermal growth factor receptor is SUMOylated","volume":"54","author":"Packham","year":"2015","journal-title":"Biochemistry"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib122","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/ncb1501","article-title":"Tyrosine phosphorylation controls PCNA function through protein stability","volume":"8","author":"Wang","year":"2006","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib123","article-title":"O-GlcNAcylation regulates epidermal growth factor receptor intracellular trafficking and signaling","volume":"119","author":"Wu","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib124","doi-asserted-by":"crossref","first-page":"8196","DOI":"10.1039\/C5OB00443H","article-title":"O-GlcNAcylation of the human epidermal growth factor receptor","volume":"13","author":"Stateva","year":"2015","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib125","doi-asserted-by":"crossref","first-page":"5567","DOI":"10.1093\/emboj\/18.20.5567","article-title":"Cell-type specific phosphorylation of threonines T654 and T669 by PKD defines the signal capacity of the EGF receptor","volume":"18","author":"Bagowski","year":"1999","journal-title":"EMBO J."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib126","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1021\/pr050113n","article-title":"Extended range proteomic analysis (ERPA): a new and sensitive LC-MS platform for high sequence coverage of complex proteins with extensive post-translational modifications-comprehensive analysis of beta-casein and epidermal growth factor receptor (EGFR)","volume":"4","author":"Wu","year":"2005","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib127","doi-asserted-by":"crossref","first-page":"13152","DOI":"10.1016\/S0021-9258(18)37684-1","article-title":"Epidermal growth factor receptor threonine and serine residues phosphorylated in vivo","volume":"263","author":"Heisermann","year":"1988","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib128","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.cell.2007.11.025","article-title":"Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer","volume":"131","author":"Rikova","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib129","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1074\/mcp.M400118-MCP200","article-title":"Phosphotyrosine signaling networks in epidermal growth factor receptor overexpressing squamous carcinoma cells","volume":"4","author":"Thelemann","year":"2005","journal-title":"Mol. Cell. Proteom.: MCP"},{"key":"10.1016\/j.cytogfr.2023.03.003_bib130","doi-asserted-by":"crossref","first-page":"7729","DOI":"10.1074\/jbc.M409056200","article-title":"Phorbol 12-myristate 13-acetate induces epidermal growth factor receptor transactivation via protein kinase Cdelta\/c-Src pathways in glioblastoma cells","volume":"280","author":"Amos","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib131","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1074\/mcp.M500089-MCP200","article-title":"Time-resolved mass spectrometry of tyrosine phosphorylation sites in the epidermal growth factor receptor signaling network reveals dynamic modules","volume":"4","author":"Zhang","year":"2005","journal-title":"Mol. Cell. Proteom."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib132","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1074\/mcp.M500070-MCP200","article-title":"Systematic analysis of the epidermal growth factor receptor by mass spectrometry reveals stimulation-dependent multisite phosphorylation","volume":"4","author":"Boeri Erba","year":"2005","journal-title":"Mol. Cell. Proteom."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib133","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1021\/pr3002029","article-title":"EGFR S1166 phosphorylation induced by a combination of EGF and gefitinib has a potentially negative impact on lung cancer cell growth","volume":"11","author":"Assiddiq","year":"2012","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib134","first-page":"3923","article-title":"Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor","volume":"63","author":"Shao","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib135","doi-asserted-by":"crossref","first-page":"8335","DOI":"10.1074\/jbc.274.12.8335","article-title":"c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function","volume":"274","author":"Biscardi","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cytogfr.2023.03.003_bib136","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/j.cub.2009.09.048","article-title":"An unbiased screen identifies DEP-1 tumor suppressor as a phosphatase controlling EGFR endocytosis","volume":"19","author":"Tarcic","year":"2009","journal-title":"Curr. Biol."}],"container-title":["Cytokine &amp; Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610123000138?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610123000138?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T11:02:10Z","timestamp":1761217330000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359610123000138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":136,"alternative-id":["S1359610123000138"],"URL":"https:\/\/doi.org\/10.1016\/j.cytogfr.2023.03.003","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiple post-translational modifications ensure EGFR functionality: Potential therapeutic targets to overcome its drug-resistance mutations","name":"articletitle","label":"Article Title"},{"value":"Cytokine & Growth Factor Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cytogfr.2023.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}